L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile
The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
27 July 2018
|
| In: |
British journal of cancer
Year: 2018, Volume: 119, Issue: 4, Pages: 480-486 |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-018-0187-6 |
| Online Access: | Resolving-System, Volltext: https://doi.org/10.1038/s41416-018-0187-6 Verlag: https://www.nature.com/articles/s41416-018-0187-6 
|
| Author Notes: | Felix KF Kommoss, Anthony N. Karnezis, Friedrich Kommoss, Aline Talhouk, Florin-Andrei Taran, Annette Staebler, C. Blake Gilks, David G. Huntsman, Bernhard Krämer, Sara Y. Brucker, Jessica N. McAlpine and Stefan Kommoss |
| Summary: | The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. |
|---|---|
| Item Description: | Gesehen am 16.12.2019 |
| Physical Description: | Online Resource |
| ISSN: | 1532-1827 |
| DOI: | 10.1038/s41416-018-0187-6 |